Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 88 of 1,261
  1. US 12116423

    Ang (1-7) derivative oligopeptides and methods for using and producing the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  2. US 12116637

    Compositions and methods for detecting and treating high grade subtypes of uterine cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  3. US 12115225

    GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  4. US 12116416

    Targeting intracellular target-binding determinants with intracellular antibodies

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  5. US 12115163

    Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

    IDEAYA Biosciences, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  6. US 12115255

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  7. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  8. US 12116343

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  9. US 12115166

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  10. WO 2024209064

    NANOÉMULSION SANS PROPYLÈNE GLYCOL

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Oct 10, 2024 · Expires Oct 5, 2044

    granted
  11. WO 2024211523

    SCHÉMAS POSOLOGIQUES DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION DE LA RECHUTE DE LA LEUCÉMIE MYÉLOÏDE AIGUË APRÈS UNE TRANSPLANTATION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES ALLOGÉNIQUES AVEC DU VÉNÉTOCLAX EN COMBINAISON AVEC DE L'AZACITIDINE

    ABBVIE INC [US] · Granted Oct 10, 2024 · Expires Oct 5, 2044

    granted
  12. WO 2024209065

    NANOÉMULSION SOUS PRESSION

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Oct 10, 2024 · Expires Oct 5, 2044

    granted
  13. AU 2023257308

    USES OF FARNESOID X RECEPTOR AGONISTS

    ALFASIGMA S P A [IT] · Granted Oct 10, 2024 · Expires Oct 5, 2044

    granted
  14. US 2024335380

    NANOEMULSION WITHOUT PROPYLENE GLYCOL

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Oct 10, 2024 · Expires Oct 5, 2044

    granted
  15. US 2024335360

    PRESSURIZED NANOEMULSION

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Oct 10, 2024 · Expires Oct 5, 2044

    granted
  16. US 12109231

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  17. US 12109272

    Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

    Corcept Therapeutics Incorporated · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  18. US 12110504

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  19. US 12109198

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  20. US 12109228

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  21. US 12109260

    Zika vaccines and immunogenic compositions, and methods of using the same

    Takeda Vaccines, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  22. US 12109190

    Urolithins as immune response enhancers

    Amazentis SA · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  23. US 12109185

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  24. US 12109197

    Combinations of β-lactam compounds and probenecid and uses thereof

    Iterum Therapeutics International Limited · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.